Identification and comprehensive profiling of high-risk multiple myeloma

In the podcast episode, the concept of high-risk multiple myeloma is discussed, focusing on various genetic abnormalities and markers that define this group. The inclusion of gene expression profiling to identify high-risk patients is highlighted, as it provides additional information beyond traditional genetic testing. The importance of considering the presence of multiple high-risk markers rather than individual abnormalities is emphasized. The outcome of the SWOG S01211 trial, which investigated the addition of elotuzumab to VRD therapy, is mentioned, showing no significant improvement in progression-free survival. The results of the OPTIMUM trial, a phase II study, are also discussed, demonstrating promising outcomes with the use of daratumumab, lenalidomide, bortezomib, and cyclophosphamide in ultra-high-risk patients. The trial achieved high response rates and a prolonged progression-free survival, suggesting the potential benefit of this treatment approach in this patient population.